Venous Thromboembolism Recurrence in Latvian Population: Single University Hospital Data

Medicina

Andris Skride¹  Dana Kigitoviča¹  Aivars Lejnieks¹  Valdis Ģībietis¹  VernersRoberts Kalējs²  Sintija Strautmane²  Kitija Meilande²  Anastasija Zaičenko²  Kristīne Maķe² 

[1] Department of Internal Diseases, Riga Stradiņš University, 4 Hipokrāta iela, LV-1079 Riga, Latvia;Faculty of Medicine, Riga Stradiņš University, 16 Dzirciema iela, LV-1007 Riga, Latvia;

关键词: venous thromboembolism;    pulmonary embolism;    recurrence;    cancer;    anticoagulation;   

DOI  :  10.3390/medicina55090510

来源: DOAJ

【 摘 要 】

Background and objectives: Recurrence of venous thromboembolism (VTE) after a primary event is common; however, no sufficient risk scores have been widely introduced in clinical practice. The aim of this study was to assess the risk factors for VTE recurrences, as well as the effect of treatment strategies on the recurrence rate in a single-center patient cohort. Materials and Methods: The prospective cohort study included consecutive patients in a single center from June 2014 till June 2018 presenting with acute VTE confirmed by imaging tests. All patients were followed up for at least one year or till death. Statistical analyses were conducted using IBM SPSS Statistics 23 and Stata 13. Competing risk of death was considered. Results: A total of 219 eligible patients were identified during the study period. Pulmonary embolism with or without deep vein thrombosis (DVT) was present in 95.9% (n = 210), isolated DVT was present in 4.1% (n = 9) of patients. The total number of documented recurrences was 13 (5.9%). Incidence rate was 5.6 per 100 person-years. Recurrent VTE predicted significantly higher mortality rate (hazard ratio (HR) 6.64 [95% CI 2.61−16.93]). In univariate analysis, active cancer was associated with higher recurrence rate (p = 0.036). In competing-risks regression model (with death as the competing risk), active cancer (subdistribution hazard ratio (SHR) 2.11 (95% CI 0.58−7.76)) did not retain statistical significance for VTE recurrence. Discontinuation and duration of anticoagulant treatment (≤6 or >6 months), and drug class in acute or long-term therapy (parenteral, vitamin K antagonist (VKA), direct oral anticoagulant (DOAC)) were not associated with recurrences (p > 0.05). Conclusions: Patients who experienced recurrent VTE had 6.6-fold higher mortality rate than patients with no recurrences. The presence of active cancer was not a statistically significant risk factor for recurrence when taking into account the competing risk of death. Duration and drug class of anticoagulation did not seem to impact recurrence rate.

【 授权许可】

Unknown